GlassScriptPhysician profile
Paul Hazelrig
NPI 1477568061
$600.55
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $456 · 2020: $104 · 2021: $40.69.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Therapeutics, INC. | $134.35 | 2019-2021 | |
| Horizon Therapeutics Plc | $70.45 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $57.36 | 2019-2020 | |
| Endo Pharmaceuticals INC. | $54.46 | 2019-2020 | |
| Bioventus LLC | $47.53 | 2019 | |
| Novartis Pharmaceuticals Corporation | $46.53 | 2019 | |
| Boston Scientific Corporation | $45.44 | 2019 | |
| Ferring Pharmaceuticals INC. | $40.55 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.25 | 2019 | |
| Zimmer Biomet Holdings, INC. | $26.53 | 2019 | |
| Amgen INC. | $22.04 | 2019 | |
| Kaleo, INC. | $17.06 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Hazelrig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.